To the best of my knowledge, the present RCT appears to be the first RCT assessing the anti‐hyperglycemic effects of MI through AMPK/PI3K/AKT pathway in obese patients with NAFLD. Here, AKT1 is linked to metabolic dysfunction-associated steatotic liver disease.